Journal of Pain and Symptom Management
Volume 28, Issue 2 , Pages 176-188 , August 2004

A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002

,Accepted 28 January 2004.

References 

  1. Marlowe KF, Chicella MF. Treatment of sickle cell pain. Pharmacotherapy. 2002;22:484–491
  2. National Institutes of Health Consensus Development Program. Symptom management in cancer: pain, depression and fatigue. Statement prepared following a National Institutes of Health State-of-the-Science Conference on Symptom Management in Cancer; Bethesda, MD; July 15-17, 2002. Available at consensus.nih.gov/ta/022/022_intro.htm.
  3. Kutner JS, Kassner CT, Nowels DE. Symptom burden at the end of life: Hospice providers' perceptions. J Pain Symptom Manage. 2001;21:473–480
  4. Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of pain in terminally ill patients. Lancet. 2001;357:1311–1315
  5. Teno JM, Weitzen S, Wetle T, Mor V. Persistent pain in nursing home residents (research letter). JAMA. 2001;285:2081
  6. Tolle SW, Tilden VP, Rosenfeld AG, Hickman SE. Family reports of barriers to optimal care of the dying. Nurs Res. 2000;49:310–317
  7. Bernabei R, Gambassi G, Lapane K, et al.  Management of pain in elderly patients with cancer. JAMA. 1998;279:1877–1882
  8. Institute of Medicine Committee on Care at the End of Life . Approaching death: improving care at the end of life. Washington, DC: National Academy Press; 1997; Available at books.nap.edu/catalog/5801.html
  9. SUPPORT Study Principal Investigators . A controlled trial to improve care for seriously ill hospitalized patients: the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (SUPPORT) JAMA. 1995;274:1591–1598
  10. Miaskowski C, Cleary J, Burney R, et al.  Guideline for the management of cancer pain in adults and children. Glenview, IL: American Pain Society; 2004;
  11. American Pain Society . Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Clinical practice guideline number 2. Glenview, IL: American Pain Society; 2002;
  12. Gaughan DM, Hughes MD, Seage GR, et al.  The prevalence of pain in pediatric human immunodeficiency virus/acquired immunodeficiency syndrome as reported by participants in the Pediatric Late Outcomes Study. (PACTG 219) Pediatrics. 2002;109:1144–1152
  13. American Pain Society . Principles of analgesic use in the treatment of acute pain and cancer pain. 4th ed. Glenview, IL: American Pain Society; 1999;
  14. World Health Organization . Cancer pain relief: with a guide to opioid availability. 2nd ed.. Geneva, Switzerland: World Health Organization; 1996; Available at whqlibdoc.who.int/publications/9241544821.pdf
  15. World Health Organization . The use of essential drugs: ninth report of the WHO expert committee (technical report series 895). Geneva, Switzerland: World Health Organization; 2000;
  16. Controlled Substances Act. Pub L No. 91-513, 84 Stat 1242, 1970.
  17. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283:1710–1714
  18. Zacny J, Bigelow G, Compton P, et al.  College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69:215–232
  19. Substance Abuse and Mental Health Services Administration and Food and Drug Administration. Prescription drug abuse rising rapidly. U.S. Department of Health and Human Services; Bethesda, MD. Press release issued January 16, 2003 as part of new initiative to battle prescription drug abuse. Available at www.rx.samhsa.gov/main.htm.
  20. National Institute on Drug Abuse. NIDA and partners announce national initiative on prescription drug misuse. NIDA, National Institutes of Health, U.S. Department of Health and Human Services; Bethesda, MD. News release issued April 10, 2001. Available at www.drugabuse.gov/MedAdv/01/NR4-10.html.
  21. Drug Enforcement Administration - Office of Diversion Control. Summary of medical examiner reports on oxycodone-related deaths. U.S. Drug Enforcement Administration; Arlington, VA. May 16, 2002. Available at www.deadiversion.usdoj.gov/drugs_ concern/oxycodone/oxycontin7.htm.
  22. Drug Enforcement Administration - Office of Diversion Control . OxyContin® diversion and abuse. Arlington, VA: U.S. Drug Enforcement Administration; October 2003; Available at www.deadiversion.usdoj.gov/drugs_concern/oxycodone/oxy_oct2003.pdf
  23. Roche T. The potent perils of a miracle drug. Time. January 2001;8:47
  24. Tough P. The alchemy of OxyContin®. NY Times Mag 2001;July 29:32–37, 52, 62.
  25. Adams N. OxyContin® use and abuse (transcript). NPR All Things Considered 2001;July 31.
  26. Neighmond P. Powerful painkiller OxyContin® and some of the negative effects it has had on drug abusers (transcript). NPR All Things Considered 2001;November 26.
  27. Clines FX, Meier B. Cancer painkillers pose new abuse threat. NY Times 2001;February 9:A1.
  28. Zwillich T. Prescription drug abuse said to be on the rise. Reuters Health 2001;April 10.
  29. Thomson Healthcare . Physicians' desk reference. 58th ed. Montvale, NJ: Thomson PDR; 2004;
  30. Hardman JG, Limbird LE, Gilman AG. Goodman and Gilman's The pharmaceutical basis of therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001;
  31. Steinbrook R. Physician-assisted suicide in Oregon—an uncertain future. N Engl J Med. 2002;346:460–464
  32. Tolle SW, Tilden VP, Hickman SE, Rosenfeld AG. Family reports of pain in dying hospitalized patients: a structured telephone survey. West J Med. 2000;172:374–377
  33. Hickman SE, Tolle SW, Tilden VP. Physicians' and nurses' perspectives on increased family reports of pain in dying hospitalized patients. J Palliat Med. 2000;3:413–418
  34. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med. 2004;5:59–65
  35. Drug Enforcement Administration - Office of Diversion Control. Automation of Reports and Consolidated Orders System. Retail drug summary reports, 1997–2002 - Report 4. Arlington, VA: U.S. Drug Enforcement Administration, 2004. Available at www. deadiversion.usdoj.gov/arcos/retail_drug_summary/ index.html.
  36. Ball J, Korper S, Woodward A. Reporting drug abuse in the emergency department. (letter) JAMA. 2000;284:564
  37. Joranson DE, Ryan KM, Gilson AM, Dahl JL. In reply to “Reporting drug abuse in the emergency department”. (letter) JAMA. 2000;284:564
  38. Substance Abuse and Mental Health Services Administration - Office of Applied Studies. Emergency department trends from the Drug Abuse Warning Network, preliminary estimates January–June 2001 with revised estimates 1994 to 2000. Rockville, MD: DAWN Series D-20, DHHS Publication No. (SMA) 02-3634, 2002. Available at dawninfo.samhsa.gov/pubs_94_02/edpubs/2001prelim/default.asp.
  39. Misra AL. Metabolism of opiates. In:  Adler ML,  Manara L,  Samanin R editor. Factors affecting the action of narcotics. New York: Raven Press; 1978;p. 297–343
  40. Martin M, Hecker J, Clark R, et al.  China white epidemic: an Eastern United States emergency department experience. Ann Emerg Med. 1991;20:158–164
  41. Mallonee E. Personal communication regarding DAWN limitations. E-mail correspondence with study authors on April 27, 2004.
  42. Substance Abuse and Mental Health Services Administration - Office of Applied Studies. Detailed emergency department tables from the Drug Abuse Warning Network 2002. Rockville, MD: 2003. Available at dawninfo.samhsa.gov/pubs_94_02/edpubs/2002final/.
  43. Mallonee E. Personal communication regarding hydromorphone estimate for 2002. E-mail correspondence with study authors on April 27, 2004.
  44. Mallonee E. Personal communication regarding RSE for hydromorphone in 2002. E-mail correspondence with study author on April 27, 2004.
  45. Crane E. Personal communication regarding hydromorphone estimate for 2002. E-mail correspondence with study author on April 14, 2004.
  46. Jacox A, Carr DB, Payne R, et al.  Management of cancer pain. Clinical practice guideline number 9, AHCPR No. 94-0592. Rockville, MD: Agency for Health Care Policy and Research, U.S. Dept of Health and Human Services, Public Health Service; 1994;
  47. Kaiko RF, Foley KM, Grabinski PY, et al.  Central nervous system excitatory effects of meperidine in cancer patients. Am Neurol Assoc. 1983;13:180–185
  48. Substance Abuse and Mental Health Services Administration - Office of Applied Studies. DAWN Emergency Department Table 5.2.0 - ED Drug Episodes by Episode Characteristics: Estimates for the coterminous U.S. by year. Rockville, MD: 2003. Available at dawninfo.samhsa.gov/pubs_94_02/edpubs/2002final/.
  49. Drug Enforcement Administration - Office of Diversion Control. OxyContin(r) Theft and Loss Incidents—Data from the DEA Drug and Loss System. 2003. Available at www.deadiversion.usdoj.gov/drugs_concern/oxycodone/oxycodone.htm.
  50. National Conference of Commissioners on Uniform State Laws. Uniform Controlled Substances Act. NCCUSL; Chicago, IL. Adopted at its Annual Conference Meeting in its One-Hundred-and-Third-Year; Chicago, IL; July 29–August 5, 1994.
  51. Joranson DE. Guiding principles of international and federal laws pertaining to medical use and diversion of controlled substances. In:  Cooper JR,  Czechowicz DJ,  Molinari SP, et al. editor. Impact of prescription drug diversion control systems on medical practice and patient care: Monograph 131. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse; 1993;p. 18–34
  52. Drug Enforcement Administration - Office of Diversion Control . The diversion of drugs and chemicals - A descriptive report of the programs and activities of DEA's Office of Diversion Control. Washington, DC: Drug Enforcement Administration; 1999; Available at www.deadiversion.usdoj.gov/pubs/program/activities/index.html
  53. United States General Accounting Office . Prescription drug monitoring: states can readily identify illegal sales and use of controlled substances. Washington, DC: United States General Accounting Office, GAO/HRD-92-115; 1992;
  54. Chi KS. Prescription drug abuse control: the Wisconsin approach. Innovations. 1983;April:1–8
  55. United States General Accounting Office . Prescription drugs and Medicaid: automated review systems can help promote safety, save money. Washington, DC: United States General Accounting Office, GAO/AIMD-96-72; 1996;
  56. Pain and Policy Studies Group. Prescription monitoring programs: trend and current status. 2003. Available at www.medsch.wisc.edu/painpolicy/ domestic/diversion.htm.
  57. Drug Enforcement Administration - Office of Diversion Control . Prescription accountability resource guide. Washington, DC: Drug Enforcement Administration; 1998; Available at www.deadiversion.usdoj.gov/pubs/program/rx_account/index.html
  58. Drug Enforcement Administration, National Alliance for Model State Drug Laws . Diversion and abuse of prescription drugs: A closer look at state prescription monitoring programs. Washington, DC: Drug Enforcement Administration; 2000; Available at www.deadiversion.usdoj.gov/pubs/program/rx_ monitor/index.html
  59. Joranson DE, Carrow GM, Ryan KM, et al.  Pain management and prescription monitoring. J Pain Symptom Manage. 2002;23:231–238
  60. United States Census Bureau - Population Division. Population estimates: April 1, 2000 to July 1, 2003. Suitland, MD: U.S. Census Bureau, 2004. Available at eire.census.gov/popest/data/states/tables/NST-EST2003-01.php.
  61. Infant Formula Act. Pub L No. 96-359, 94 Stat 1190, 1980.
  62. Code of Federal Regulations. Title 21 CFR Sec.1301.76(b). Available at www.access.gpo.gov/nara/cfr/waisidx_03/21cfr1301_03.html.
  63. Drug Enforcement Administration . Pharmacist's manual: An informational outline of the Controlled Substances Act of 1970. Washington, DC: U.S. Department of Justice; 2001;
  64. Controlled Substance Registrant Protection Act. Pub L No. 98-305, 18 U.S.C. 2118(a), 1984.
  65. Butterfield F. Theft of painkiller reflects its popularity on the street. NY Times 2001;July 7:A6.
  66. Drug Enforcement Administration - Office of Diversion Control. Action plan to prevent the diversion and abuse of OxyContin®. U.S. Drug Enforcement Administration; Arlington, VA. June 22, 2001. Available at www.deadiversion.usdoj.gov/drugs_ concern/oxycodone/abuse_oxy.htm.
  67. Pain and Policy Studies Group . Achieving balance in federal and state pain policy: a guide to evaluation, 2nd ed. Madison, WI: University of Wisconsin Comprehensive Cancer Center; 2003; Available at www.medsch.wisc.edu/painpolicy/2003_balance/
  68. World Health Organization . Achieving balance in national opioids control policy: guidelines for assessment. Geneva, Switzerland: World Health Organization; 2000; Available at www.medsch.wisc.edu/painpolicy/publicat/00whoabi/00whoabi.htm
  69. American Medical Association-House of Delegates . Protection for physicians who prescribe pain medication H-120.960. Chicago, IL: American Medical Association; 2003;
  70. Massachusetts State Board of Pharmacy. State board of pharmacy amends its policy on OxyContin®. Boston, MA: 2002. Available at www.state.ma.us/reg/services/press/nw060002.htm.
  71. Cancer Pain Management Policy Review Group . American Cancer Society position statement on regulatory barriers to quality cancer pain management. National Government Relations Department, American Cancer Society; 2001;
  72. Cancer Pain Management Policy Review Group . American Cancer Society position statement on Medicaid prior authorization for pain medications. National Government Relations Department, American Cancer Society; 2001;
  73. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26:655–667
  74. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888–1899
  75. American Geriatrics Society Panel on Persistent Pain in Older Persons . The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50:S205–S224
  76. Robinson DE. Prescribing controlled substances for cancer pain: position paper of the Utah Division of Occupational and Professional Licensing. J Pharm Care Pain Symptom Control. 1993;1:109–112
  77. National Institute on Drug Abuse . Prescription drugs: abuse and addiction. NIDA research report. NIH Publication No. 01-4881. Rockville, MD: NIDA; 2001;
  78. Dannemiller Memorial Educational Foundation. Lawful opioid prescribing and prevention of diversion: Issues and insights. San Antonio, TX: CD-ROM for 2 CME/CPE Credit Hours, 2001.
  79. California Academy of Family Physicians, CorTexT/Mind Matters Educational Seminars . Lawful prescribing and prevention of diversion. USA: PharmaCom Group, Inc; 2001; Available at www.familydocs. org/
  80. National Pain Education Council . Assessment and management of aberrant drug-related behavior in the chronic pain patient. Deerfield, IL: Discovery International; 2002;
  81. American Society of Addiction Medicine. Pain and addiction medicine. 2003. Available at www.asam. org/pain/pain_and_addiction_medicine.htm.
  82. Drug Enforcement Administration, Last Acts, Pain and Policy Studies Group, American Academy of Hospice and Palliative Medicine, American Academy of Pain Medicine, American Alliance of Cancer Pain Initiatives. Promoting pain relief and preventing abuse of pain medications: A critical balancing act. Washington, DC: Last Acts, 2001. Available at www. medsch.wisc.edu/painpolicy/dea01.htm.
  83. National Association of State Controlled Substances Authorities. NASCSA Resolution 99-01. A Resolution Endorsing the Model Guidelines for the Use of Controlled Substances for the Treatment of Pain. Adopted at the NASCSA 15th Annual Educational Conference; Coeur d'Alene, Idaho; October 29, 1999. Available at www.nascsa.org/resolutions. htm.
  84. National Association of Attorneys General. Resolution calling for a balanced approach to promoting pain relief and preventing abuse of pain medications. Adopted at the National Association of Attorneys General Spring Meeting; Washington, DC; March 17–20, 2003.

PII: S0885-3924(04)00182-4

doi: 10.1016/j.jpainsymman.2004.01.003

Journal of Pain and Symptom Management
Volume 28, Issue 2 , Pages 176-188 , August 2004

Article Tools